Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,502
  • Shares Outstanding, K 104,320
  • Annual Sales, $ 70 K
  • Annual Income, $ -71,910 K
  • 36-Month Beta 1.68
  • Price/Sales 1,000.02
  • Price/Cash Flow N/A
  • Price/Book 3.24
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.88
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/07/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.61 +13.93%
on 06/12/18
0.79 -12.03%
on 06/06/18
-0.02 (-2.93%)
since 05/18/18
3-Month
0.61 +13.93%
on 06/12/18
0.87 -20.11%
on 03/21/18
-0.13 (-15.24%)
since 03/19/18
52-Week
0.61 +13.93%
on 06/12/18
1.52 -54.28%
on 10/02/17
-0.31 (-31.19%)
since 06/19/17

Most Recent Stories

More News
New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus Therapeutics, and Weyerhaeuser -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CNA Financial Corporation (NYSE:CNA),...

WY : 36.99 (-0.35%)
CNA : 47.77 (+0.46%)
HES : 61.40 (-0.32%)
INFI : 1.79 (+2.87%)
RGLS : 0.69 (unch)
AN : 50.22 (+1.43%)
Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global, and MedEquities Realty Trust -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regulus Therapeutics Inc. (NASDAQ:RGLS),...

AIRG : 9.12 (-1.72%)
KORS : 67.02 (-2.30%)
RGLS : 0.69 (unch)
CDK : 64.15 (-0.22%)
HRTG : 16.27 (+1.50%)
MRT : 10.54 (+0.67%)
Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the first quarter...

RGLS : 0.69 (unch)
Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has initiated a Phase I...

RGLS : 0.69 (unch)
Kathryn J. Collier Joins Regulus Board of Directors

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced Kathryn J. Collier has joined the...

RGLS : 0.69 (unch)
Regulus to Present at the Needham Healthcare Conference

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and Chief...

RGLS : 0.69 (unch)
Quotidian Technical Highlights on Selected Biotech Stocks -- Portola Pharma, Protalix BioTherapeutics, Radius Health, and Regulus Therapeutics

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on PTLA, PLX, RDUS, and RGLS which can be accessed for free by signing up to www.wallstequities.com/registration....

RDUS : 31.31 (+2.05%)
RGLS : 0.69 (unch)
PTLA : 42.77 (+3.28%)
Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth...

RGLS : 0.69 (unch)
Regulus Therapeutics Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Regulus Therapeutics Inc. (NASDAQ: RGLS) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at 5:00 PM Eastern...

RGLS : 0.69 (unch)
Regulus to Provide Fourth Quarter and Year-end 2017 Financial Results on March 7, 2018

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will provide fourth quarter and...

RGLS : 0.69 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade RGLS with:

Business Summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and...

See More

Key Turning Points

2nd Resistance Point 0.75
1st Resistance Point 0.72
Last Price 0.69
1st Support Level 0.68
2nd Support Level 0.66

See More

52-Week High 1.52
Fibonacci 61.8% 1.17
Fibonacci 50% 1.07
Fibonacci 38.2% 0.96
Last Price 0.69
52-Week Low 0.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar